Cited by 1,557Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Open access

Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto, Antonio M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200106283442601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200106283442601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citation
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952

Show all 27 references

Sorted by citations

Items 501–600 of 998

Is Dressler Syndrome Dead?
Bendjelid, K., & Pugin, J. (2004) · CHEST Journal · doi:10.1378/chest.126.5.1680 · Cited by 55
Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non–Q-wave acute myocardial infarction
Correia, L. C. L., Sposito, A. C., Lima, J. C., de Magalhães, L. P., Passos, L. C. S., Rocha, M. D. S., D’Oliveira, A., & Esteves, J. P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00630-1 · Cited by 55
Statin use and the risk of Alzheimer's disease: The MIRAGE Study
Green, R. C., McNagny, S. E., Jayakumar, P., Cupples, L. A., Benke, K. S., Farrer, L. A., & MIRAGE Study Group (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.02.003 · Cited by 55
Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease
Liu, L., Zhao, S., Cheng, Y.-C., & Li, Y.-L. (2003) · Clinical Chemistry · doi:10.1373/49.8.1347 · Cited by 55
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease
Fortmann, S. P., Ford, E. S., Criqui, M. H., Folsom, A. R., Harris, T. B., Hong, Y., Pearson, T. A., Siscovick, D. S., Vinicor, F., & Wilson, P. W. F. (2004) · Circulation · doi:10.1161/01.cir.0000148982.95775.bf · Cited by 55
Statin Therapy for Cardiac Hypertrophy and Heart Failure
Liao, J. K. (2004) · Journal of Investigative Medicine · doi:10.1136/jim-52-04-33 · Cited by 55
Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values
Tsimihodimos, V., Kostoula, A., Kakafika, A. I., Bairaktari, E. T., Tselepis, A. D., Mikhailidis, D. P., & Elisaf, M. (2004) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840400900i105 · Cited by 55
Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials
D’Ugo, E., Libby, P., & De Caterina, R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0246 · Cited by 54
New frontiers in obstructive sleep apnoea
Ayas, N., Hirsch, A. A. J., Laher, I., Bradley, T. D., Malhotra, A., Polotsky, V. Y., & Tasali, E. (2014) · Clinical Science · doi:10.1042/cs20140070 · Cited by 58
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Renal Transplant Recipients
Rigatto, C. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16026.x · Cited by 54
Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study
Kim, J. Y., Hyun, Y. J., Jang, Y., Lee, B. K., Chae, J. S., Kim, S. E., Yeo, H. Y., Jeong, T., Jeon, D. W., & Lee, J. H. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.3.630 · Cited by 54
High-Sensitivity C-Reactive Protein and Risk of Sepsis
Wang, H. E., Shapiro, N. I., Safford, M. M., Griffin, R. L., Judd, S. E., Rodgers, J. B., Warnock, D. G., Cushman, M., & Howard, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069232 · Cited by 54
Contemporary Results of Carotid Endarterectomy for Asymptomatic Carotid Stenosis
Woo, K., Garg, J., Hye, R. J., & Dilley, R. B. (2010) · Stroke · doi:10.1161/strokeaha.110.578856 · Cited by 54
Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease
Halkin, A., & Keren, G. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01001-4 · Cited by 54
Role of Inflammation and Its Treatment in ESRD Patients
Kaysen, G. A. (2002) · Blood Purification · doi:10.1159/000046988 · Cited by 54
Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial
Ridker, P. M. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2990 · Cited by 54
Self-citation
The role of statins in clinical medicine -LDL - cholesterol lowering and beyond
Rutishauser, J. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11170 · Cited by 53
Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial
Buchowski, M. S., Hongu, N. K., Acra, S. A., Wang, L., Warolin, J., & Roberts, L. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047079 · Cited by 53
Plasma Cathepsin S and Cystatin C Levels and Risk of Abdominal Aortic Aneurysm: A Randomized Population–Based Study
Lv, B., Lindholt, J. S., Cheng, X. C., Wang, J., & Shi, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041813 · Cited by 53
Accelerated atherosclerosis in inflammatory rheumatic diseases
Haskard, D. O. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410010281 · Cited by 53
Role of C-reactive protein in the assessment of cardiovascular risk
Jialal, I., & Devaraj, S. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03110-7 · Cited by 53
High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease
Rosenson, R. S., & Köenig, W. (2002) · Current Opinion in Cardiology · doi:10.1097/00001573-200207000-00001 · Cited by 53
The Levels of Inflammatory Markers in the Treatment of Stroke Study (Limits): Inflammatory Biomarkers as Risk Predictors after Lacunar Stroke
Elkind, M. S. V., Luna, J. M., Coffey, C. S., McClure, L. A., Liu, K. M., Spitalnik, S. L., Paik, M. C., Roldan, A., White, C. L., Hart, R. G., et al. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00420.x · Cited by 51
hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reactive Protein and High-Density Lipoprotein Levels
Ansell, B. J., Watson, K. E., Weiss, R. E., & Fonarow, G. C. (2003) · Heart Disease · doi:10.1097/01.hdx.0000050407.62572.de · Cited by 52
Enfermedades cardiovasculares en la mujer: ¿por qué ahora?
Alfonso, F., Bermejo, J., & Segovia, J. (2006) · Revista Española de Cardiología · doi:10.1157/13086083 · Cited by 52
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors
Koziński, M., Ostrowska, M., Fabiszak, T., Navarese, E. P., Paciorek, P., Grześk, G., Kubica, J., & Adamski, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0915 · Cited by 51
Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.
Zhang, J., Cui, X., Yan, Y., Li, M., Yang, Y. J., Wang, J., & Zhang, J. (2016) · Europe PMC (PubMed Central) · Cited by 50
Statins in the treatment of depression: Hype or hope?
Köhler‐Forsberg, O., Otte, C., Gold, S. M., & Østergaard, S. D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107625 · Cited by 52
CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events?
HEDMAN, A. G., Larsson, P. T., Alam, M., Wallén, N. H., Nordlander, R., & Samad, B. A. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.09.004 · Cited by 51
Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease
Horne, B. D., Muhlestein, J. B., Carlquist, J. F., Bair, T. L., Madsen, T. E., Hart, N. I., & Anderson, J. L. (2003) · Circulation · doi:10.1161/01.cir.0000045668.71683.92 · Cited by 51
CVD screening in low-risk, asymptomatic adults: clinical trials needed
Polonsky, T. S., & Greenland, P. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.114 · Cited by 50
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 52
C-reactive protein predicts further ischemic events in transient ischemic attack patients
Purroy, F. F., Montaner, J., Molina, C. A., Delgado, P., Arenillas, J. F., Chacón, P. M., Quintana, M., & Álvarez‐Sabín, J. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00715.x · Cited by 50
Hypercoagulation Testing in Ischemic Stroke
Rahemtullah, A., & Cott, E. M. V. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-890-htiis · Cited by 50
Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients
Sabbatino, F., Conti, V., Liguori, L., Polcaro, G., Corbi, G., Manzo, V., Tortora, V., Carlomagno, C., Vecchione, C., Filippelli, A., et al. (2021) · Life · doi:10.3390/life11020105 · Cited by 50
Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein
Kluft, C., & de Maat, M. P. M. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00293-8 · Cited by 49
The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong, H. T. (2005) · QJM · doi:10.1093/qjmed/hci093 · Cited by 49
Do statins have a role in preventing or treating sepsis?
Novack, V., Terblanche, M., & Almog, Y. (2006) · Critical Care · doi:10.1186/cc3972 · Cited by 49
Effects of statins in reducing thrombotic risk and modulating plaque vulnerability
Libby, P., & Aikawa, M. (2003) · Clinical Cardiology · doi:10.1002/clc.4960261305 · Cited by 49
Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit
Wright, R. S., Murphy, J. G., Bybee, K. A., Kopecky, S. L., & Lablanche, J. M. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.10.1085 · Cited by 49
Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide
Alam, S. R., Stirrat, C., Richards, J. M. J., Mirsadraee, S., Semple, S. I. K., Tse, G. H., Henriksen, P. A., & Newby, D. E. (2015) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-015-0183-4 · Cited by 48
Pathophysiology, Diagnosis, and Management of Dyslipidemia
Gau, G. T., & Wright, R. S. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2006.03.001 · Cited by 49
Immunomodulatory effects of HMG-CoA reductase inhibitors.
Danesh, F. R., Añel, R., Zeng, L., Lomasney, J. W., Sahai, A., & Kanwar, Y. S. (2003) · PubMed · Cited by 48
The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials
Tabrizi, R., Tamtaji, O. R., Lankarani, K. B., Mirhosseini, N. Z., Akbari, M., Dadgostar, E., Peymani, P., & Asemi, Z. (2018) · Food & Function · doi:10.1039/c8fo01259h · Cited by 48
Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice
Visnegarwala, F., Maldonado, M., Sajja, P., Minihan, J. L., Rodriguez-Barradas, M. C., Ong, O., Lahart, C. J., Hasan, M. Q., Balasubramanyam, A., & White, A. C. (2003) · Journal of Infection · doi:10.1016/j.jinf.2003.09.006 · Cited by 48
Uremia-associated immune defect: The IL-10–CRP axis
Girndt, M., Ulrich, C., Kaul, H., Sester, U., Sester, M., & Köhler, H. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.14.x · Cited by 48
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?
Blake, G. J., & Ridker, P. M. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00227.2003 · Cited by 47
Self-citation
Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial
Tam, L., Li, E. K., Shang, Q., Tomlinson, B., Lee, V. W. Y., Lee, K., Li, M., Kuan, W.-P., Li, T. K., Tseung, L., et al. (2011) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2011.586649 · Cited by 47
Can statins prevent pregnancy complications?
Girardi, G. (2013) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2013.07.005 · Cited by 46
The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial
Abd, T. T., Eapen, D. J., Bajpai, A., Goyal, A., Dollar, A. L., & Sperling, L. S. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0164-5 · Cited by 47
CRP in Cardiovascular Disease
Karakas, M., & Köenig, W. (2009) · Herz · doi:10.1007/s00059-009-3305-7 · Cited by 49
Prediction of Recurrent Events by D-Dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) study
Menown, I. B. A., Mathew, T. P., Gracey, H., Nesbitt, G. S., Murray, P., Young, I. S., & Adgey, A. A. J. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00169-8 · Cited by 47
Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels
Rizos, E., Kostoula, A., Elisaf, M., & Mikhailidis, D. P. (2002) · Angiology · doi:10.1177/000331970205300304 · Cited by 47
Investigating cardiovascular risk reduction ? the Rosuvastatin GALAXY Programme?
Schuster, H., & Fox, J. C. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.5.1187 · Cited by 47
Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease
Tonelli, M., Collins, D., Robins, S., Bloomfield, H., & Curhan, G. C. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)01082-0 · Cited by 56
Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population
Coen, P. M., Flynn, M. G., Markofski, M. M., Pence, B. D., & Hannemann, R. E. (2010) · Metabolism · doi:10.1016/j.metabol.2010.05.002 · Cited by 47
C-reactive protein levels in patients at cardiovascular risk: EURIKA study
Halcox, J., Roy, C., Tubach, F., Banegas, J. R., Dallongeville, J., Backer, G. D., Güallar, E., Sazova, O., Medina, J., Perk, J., et al. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-25 · Cited by 47
Effects of Pitavastatin on Lipid Profiles and High-Sensitivity CRP in Japanese Subjects with Hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigatars
Koshiyama, H., Taniguchi, A., Tanaka, K., Kagimoto, S., Fujioka, Y., Hirata, K., Nakamura, Y., Iwakura, A., Hara, K., Yamamoto, T., et al. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e581 · Cited by 46
Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy
Tamargo, J. L., Caballero, R., Gómez, R. J., Núñez, L., Vaquero, L. M., & Delpón, E. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.12.002 · Cited by 46
Cytokines as new treatment targets in chronic heart failure
Damås, J. K., Gullestad, L. L., & Aukrust, P. (2001) · Trials · doi:10.1186/cvm-2-6-271 · Cited by 46
Connecting the role of C-reactive protein and statins in cardiovascular disease
Ridker, P. M. (2003) · Clinical Cardiology · doi:10.1002/clc.4960261508 · Cited by 46
Self-citation
Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein
Chu, A. Y., Guilianini, F., Barratt, B. J., Nyberg, F., Chasman, D. I., & Ridker, P. M. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.961847 · Cited by 45
Self-citation
The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels
Choudhry, N. K., Patrick, A. R., Glynn, R. J., & Avorn, J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.059 · Cited by 45
Mediators of the Effect of Body Mass Index on Coronary Heart Disease
Lu, Y., Hajifathalian, K., Rimm, E. B., Ezzati, M., & Danaei, G. (2015) · Epidemiology · doi:10.1097/ede.0000000000000234 · Cited by 45
Lovastatin attenuates nerve injury in an animal model of Guillain–Barré syndrome
Sarkey, J. P., Richards, M. P., & Stubbs, E. B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04309.x · Cited by 44
Interleukin-18 and the risk of future cardiovascular disease among initially healthy women
Everett, B. M., Bansal, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.015 · Cited by 43
Self-citation
Rapid Electrochemiluminoimmunoassay of Human C-Reactive Protein at Planar Disposable Oxide-Coated Silicon Electrodes
Ala‐Kleme, T., Mäkinen, P., Ylinen-Hinkka, T., Väre, L., Kulmala, S., Ihalainen, P., & Peltonen, J. P. K. (2005) · Analytical Chemistry · doi:10.1021/ac051157i · Cited by 45
Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention
Gotto, A. M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.026 · Cited by 46
Self-citation
Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia
Blake, G. J., Ridker, P. M., & Kuntz, K. M. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00074-3 · Cited by 44
Self-citation
Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?
Gotto, A. M. (2011) · PubMed Central · Cited by 44
Self-citation
C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndrome
Sheikh, A., Yahya, S., Sheikh, N., & Sheikh, A. (2012) · Heart Views · doi:10.4103/1995-705x.96660 · Cited by 44
Biomarkers in Cardiovascular Clinical Trials: Past, Present, Future
Halim, S. A., Newby, L. K., & Ohman, E. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165787 · Cited by 44
Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer
Addison, D., Lawler, P. R., Emami, H., Janjua, S., Staziaki, P. V., Hallett, T. R., Hennessy, O., Lee, H., Szilveszter, B., Lu, M. T., et al. (2018) · Journal of Stroke · doi:10.5853/jos.2017.01802 · Cited by 44
Old and new cardiovascular risk factors: from unresolved issues to new opportunities
Maas, R., & Böger, R. H. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00028-x · Cited by 44
La inflamación en los síndromes coronarios agudos: mecanismos e implicaciones clínicas
Angiolillo, D. J., Biasucci, L. M., Liuzzo, G., & Crea, F. (2004) · Revista Española de Cardiología · doi:10.1016/s0300-8932(04)77128-6 · Cited by 44
Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells
de la Monte, S. M., Chen, G., Rivera, E. J., & Wands, J. R. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3305-3 · Cited by 46
Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy
Stauffer, B. L., Hoetzer, G. L., Smith, D. T., & DeSouza, C. A. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00360.2003 · Cited by 44
Risk Stratification and Prognostic Implication of Plasma Biomarkers in Nondiabetic Patients With Stable Coronary Artery Disease
Leu, H., Lin, C.-P., Lin, W.-T., Wu, T.-C., & Chen, J. (2004) · CHEST Journal · doi:10.1378/chest.126.4.1032 · Cited by 44
Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease
Whiting, B. M., Anderson, J. L., Muhlestein, J. B., Horne, B. D., Bair, T. L., Pearson, R. R., & Carlquist, J. F. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.08.034 · Cited by 44
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 44
Self-citation
Relationship between the Hemoglobin-to-Red Cell Distribution Width Ratio and All-Cause Mortality in Septic Patients with Atrial Fibrillation: Based on Propensity Score Matching Method
Wang, J., Chen, Z., Yang, H., Li, H., Chen, R., & Yu, J. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9110400 · Cited by 43
Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?
Hasselbalch, H. C., & Riley, C. H. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.12.018 · Cited by 43
High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease
Sara, J. D. S., Prasad, M., Zhang, M., Lennon, R. J., Herrmann, J., Lerman, L. O., & Lerman, A. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.035 · Cited by 43
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 43
Effect of atorvastatin and pravastatin on serum C-reactive protein
Kent, S. M., Flaherty, P. J., Coyle, L. C., Markwood, T. T., & Taylor, A. J. (2003) · American Heart Journal · doi:10.1067/mhj.2003.34 · Cited by 43
Prevention of Cardiovascular Ischemic Events
Genest, J. J., & Pedersen, T. R. (2003) · Circulation · doi:10.1161/01.cir.0000067881.26274.bd · Cited by 43
Physical Activity, High-Sensitivity C-Reactive Protein, and Total and Cardiovascular Disease Mortality in Type 2 Diabetes
Vepsäläinen, T., Soinio, M., Marniemi, J., Lehto, S., Juutilainen, A., Laakso, M., & Rönnemaa, T. (2011) · Diabetes Care · doi:10.2337/dc11-0469 · Cited by 42
Red blood cell distribution width is a significant prognostic marker in advanced heart failure, independent of hemoglobin levels.
Tseliou, E., Terrovitis, J. V., Kaldara, E. E., Ntalianis, A., Repasos, E., Katsaros, L., Margari, Z. J., Matsouka, C., Toumanidis, S. T., Nanas, S., et al. (2014) · PubMed · Cited by 41
A hook effect-free immunochromatographic assay (HEF-ICA) for measuring the C-reactive protein concentration in one drop of human serum
Oh, J., Joung, H., Han, H. S., Kim, J. K., & Kim, M. (2018) · Theranostics · doi:10.7150/thno.24034 · Cited by 43
Targeting Inflammation After Myocardial Infarction
Mahtta, D., Sudhakar, D., Koneru, S., Silva, G. V., Alam, M., Virani, S. S., & Jneid, H. M. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01358-2 · Cited by 43
Statins: A potential role in the management of osteoarthritis?
Baker, J. F., Walsh, P. M., & Mulhall, K. J. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.02.035 · Cited by 43
Red Cell Distrubition Width (RDW): A novel risk factor for cardiovascular disease
Uyarel, H., Işık, T., Ayhan, E., & Ergelen, M. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.126 · Cited by 43
Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population
Lai, M.-M., Li, C.-I., Kardia, S. L. R., Liu, C.-S., Lin, W., Lee, Y.-D., Chang, P.-C., Lin, C., & Li, T.-C. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-429 · Cited by 42
Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease
Herrington, D. M., Kesler, K. L., Reiber, J. H. C., Davis, W. W., Brown, W. V., Helms, R. W., Mallon, S. M., & Raines, J. K. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00254-0 · Cited by 42
Traditional and Emerging Risk Factors for Cardiovascular Disease
Eaton, C. B. (2005) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2005.09.009 · Cited by 43
Biomarkers of exposure and potential harm in adult smokers of 3–7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers
Zedler, B. K., Kinser, R. D., Oey, J., Nelson, B. L., Roethig, H. J., Walk, R., Kühl, P. G., Rustemeier, K., Schepers, G., von Holt, K., et al. (2006) · Biomarkers · doi:10.1080/13547500600576260 · Cited by 42
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Dandona, P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.333 · Cited by 42
Statin Therapy
Yeung, A. C., & Tsao, P. S. (2002) · Circulation · doi:10.1161/01.cir.0000023397.12047.03 · Cited by 42
Metabolic biomarkers for predicting cardiovascular disease
Brown, J. R., & Montgomery (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s30378 · Cited by 42
Statin Prescribing in the Elderly in the Netherlands
Vooght, M. G.-D., der Zee, A. H. M., Schalekamp, T., Mantel-Teeuwisse, A. K., & Jansen, P. A. F. (2010) · Drugs & Aging · doi:10.2165/11537330-000000000-00000 · Cited by 41

Authors: Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
Affiliations: Brigham and Women's Hospital (US)
University of North Texas Health Science Center (US)
Wilford Hall Ambulatory Surgical Center (US)
ORCID: Ridker, Paul M.
Rifai, Nader
Weis, Stephen E.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-06-28
Volume: 344
Issue: 26
Pages: 1959-1965
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200106283442601
OpenAlex: W2316243284
Cited by: 1,557
References: 27
Citations by year: 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
FWCI: 158.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Doris Duke Charitable Foundation
American Heart Association
Fondation Leducq
National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
MeSH terms: Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks